"Payviders" are responsible for the cost of avoidable readmissions and emergency room visits, but they lose sight of patients once they go home.
News|Articles|February 5, 2026
3 takeaways from Cigna’s 2025 earnings call
Author(s)Denise Myshko
Cigna reported 11% revenue growth for 2025. Company executives focused on several key issues in its call with investors: its settlement with the Federal Trade Commission, a transformation announced last year to move to a rebate-free model in pharmacy benefits, and a focus on patient affordability.
Advertisement
Advertisement
The Cigna Group reported strong 2025 financial results this morning, just a day after its settlement with federal regulators was announced. For the full year 2025, the company saw total revenue increase 11% to $274.9 billion compared with 2024. Adjusted earnings per share were $29.84 for 2025, representing 9% growth, and Cigna executives project it will be at least $30.25 per share for 2026.
Related to this article
Jenny Goins, interim head of the National Alliance of Healthcare Purchaser Coalitions, says employers need the same visibility into medical benefits that a new Department of Labor rule gives them into PBM compensation.
Only 19% of community oncologists use AI predictive models. Prerna Mewawalla, M.D., outlines six ways AI can already help in myeloma care.
Jamilia Sherls, DNP, says health systems should track vaccine coverage closely and look to AAP schedules if federal guidance isn't evidence-based.
Model N's Jesse Mendelsohn explains why drug manufacturers argued that a 340B rebates instead of upfront discounts will avoid an overlapping maximum fair price and 340B discounts
People with ADHD had a 70% higher risk of death from any cause in a 19-study meta-analysis, with excess deaths from suicide, injury and natural causes.
Bronchiectasis affected 221.6 per 100,000 people in the U.S. over five years, which is higher than earlier national estimates, according to a study published in CHEST.
Cepheid’s Xpert Respiratory Panel, which tests one swab for nine viruses and four bacteria, is now certified for sale in Europe under the IVDR.
Advertisement
Advertisement